📰 Activating Construct News
Page 3 - Activating Construct News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Activating Construct. Real-time updates on events, politics, business and more.
May 13, 2023
Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Rating) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totalling 761,200 shares, a growth of 115.5% from the April 15th total of 353,200 shares. Based on an average daily trading volume, of 305,500 shares, the short-interest ratio […]
May 12, 2023
Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Rating) saw a significant increase in short interest in April. As of April 30th, there was short interest totalling 761,200 shares, an increase of 115.5% from the April 15th total of 353,200 shares. Currently, 3.3% of the company’s stock are sold short. Based on an average daily volume of […]
May 2, 2023
Shares of Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Rating) have been assigned a consensus rating of “Moderate Buy” from the ten research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month […]
May 1, 2023
Harpoon Therapeutics (NASDAQ:HARP – Get Rating) and Novavax (NASDAQ:NVAX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations. Earnings and Valuation This table compares Harpoon Therapeutics and Novavax’s […]
April 26, 2023
Shares of Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Rating) were down 3.7% during trading on Monday . The company traded as low as $0.58 and last traded at $0.59. Approximately 352,029 shares were traded during trading, a decline of 15% from the average daily volume of 413,621 shares. The stock had previously closed at $0.61. […]
April 18, 2023
Preclinical results for HPN328 suggest potential for long-term anti-tumor immunity and durable responses in patients, as well as utility of combining anti-PD-L1 antibodies to enhance anti-tumor... | June 19, 2023
April 17, 2023
Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and... | April 17, 2023
April 17, 2023
Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic...
April 7, 2023
Harpoon Therapeutics (NASDAQ:HARP – Get Rating) had its price objective reduced by Canaccord Genuity Group from $16.00 to $8.00 in a research report sent to investors on Monday morning, Benzinga reports. They currently have a buy rating on the stock. Other analysts also recently issued research reports about the stock. HC Wainwright decreased their price […]
April 5, 2023
Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Rating) – Stock analysts at Cantor Fitzgerald upped their FY2023 earnings per share estimates for Harpoon Therapeutics in a report released on Wednesday, March 29th. Cantor Fitzgerald analyst J. Kim now forecasts that the company will post earnings of ($1.11) per share for the year, up from their prior […]